Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3093 |
|
Actual shortage: | 247 (8%) | |
Anticipated shortage: | 14 (0%) | |
Avoided shortage: | 9 (0%) | |
Resolved: | 2823 (91%) | |
Discontinuation Reports |
356 |
|
To be discontinued: | 22 (6%) | |
Discontinued: | 334 (94%) | |
Reversed: | 0 (0%) | |
Late reports |
142 (4%) |
|
Overdue reports |
32 (11%) |
Shortage reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
APO-GABAPENTIN | 300MG | CAPSULE | Resolved | 2017-06-06 | 2017-08-16 | 12064 |
APO-GABAPENTIN | 100MG | CAPSULE | Resolved | 2017-08-21 | 2017-10-04 | 20000 |
APO-GABAPENTIN | 300MG | CAPSULE | Resolved | 2017-11-09 | 2017-12-19 | 28726 |
APO-GABAPENTIN | 100MG | CAPSULE | Resolved | 2017-11-28 | 2018-02-21 | 30998 |
APO-GABAPENTIN | 100MG | CAPSULE | Resolved | 2018-02-26 | 2018-04-24 | 41145 |
APO-GABAPENTIN | 300MG | CAPSULE | Resolved | 2018-04-02 | 2018-08-21 | 44497 |
APO-GAIN LIQ 20MG/ML | 20MG | LIQUID | Resolved | 2017-04-12 | 2018-02-26 | 6554 |
APO-GATIFLOXACIN | 0.3% | SOLUTION | Resolved | 2023-09-28 | 2023-11-24 | 205486 |
APO-GATIFLOXACIN | 0.3% | SOLUTION | Resolved | 2024-03-27 | 2024-04-12 | 223555 |
APO-GEFITINIB | 250MG | TABLET | Resolved | 2022-04-14 | 2022-06-24 | 158819 |
APO-GEMFIBROZIL | 600MG | TABLET | Resolved | 2017-03-11 | 2019-11-26 | 610 |
APO-GEMFIBROZIL CAP 300MG USP | 300 MG | CAPSULE | Resolved | 2017-03-11 | 2019-06-12 | 607 |
APO-GLICLAZIDE | 80MG | TABLET | Resolved | 2017-10-17 | 2018-05-22 | 26159 |
APO-GLICLAZIDE | 80MG | TABLET | Resolved | 2018-05-01 | 2018-09-11 | 47680 |
APO-GLICLAZIDE | 80MG | TABLET | Resolved | 2020-02-13 | 2020-04-14 | 105997 |
APO-GLICLAZIDE | 80MG | TABLET | Resolved | 2020-09-02 | 2020-09-14 | 123561 |
APO-GLICLAZIDE MR | 30MG | TABLET (EXTENDED-RELEASE) | Resolved | 2020-10-28 | 2021-02-16 | 127342 |
APO-GLICLAZIDE | 80MG | TABLET | Resolved | 2022-01-28 | 2022-02-08 | 153780 |
APO-GLICLAZIDE | 80MG | TABLET | Resolved | 2022-12-16 | 2022-12-23 | 178760 |
APO-GLICLAZIDE | 80MG | TABLET | Resolved | 2023-04-21 | 2023-06-29 | 189988 |
Discontinuation reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |
APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
APO-CAPTO TAB 6.25MG | 6.25MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60339 |
APO-CARBAMAZEPINE | Discontinued | 2020-02-19 | 2020-02-19 | 106679 |